-
1 Comment
Jafron Biomedical Co.,Ltd is currently in a long term uptrend where the price is trading 4.7% above its 200 day moving average.
From a valuation standpoint, the stock is 264.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 35.1.
Jafron Biomedical Co.,Ltd's total revenue rose by 38.0% to $635M since the same quarter in the previous year.
Its net income has increased by 62.1% to $248M since the same quarter in the previous year.
Finally, its free cash flow grew by 99.4% to $320M since the same quarter in the previous year.
Based on the above factors, Jafron Biomedical Co.,Ltd gets an overall score of 4/5.
| Industry | Medical Devices |
|---|---|
| Exchange | SHE |
| CurrencyCode | CNY |
| ISIN | CNE100002995 |
| Sector | Healthcare |
| PE Ratio | 30.78 |
|---|---|
| Market Cap | 16B |
| Beta | 0.48 |
| Target Price | 25.09 |
| Dividend Yield | 3.9% |
Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300529.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
